|
|
Kynurenine |
|
Vaxjo ID |
246 |
|
Vaccine Adjuvant Name |
Kynurenine |
|
Adjuvant VO ID |
VO_0005733
|
|
Description |
An endogenous immunosuppressive molecule, Kynurenine promotes Treg induction, suppresses T cell and dendritic cell activation, and modulates Th1/Th2 balance. It acts via the aryl hydrocarbon receptor (AHR) pathway |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
Kynurenine (Kyn) is an endogenous substance that can inhibit the natural killer cell and T cell proliferation and promote the differentiation of naïve T cells into regulatory T cells (Tregs) |
|
Structure |
Small-molecule, aromatic amino acid derivative from tryptophan |
|
Molecular Weight |
208.2 g/mol |
|
Storage |
Commercially obtained (Sigma K8625) |
|
Dosage |
200 µg per injection, co-administered with 10¹¹ PFU of GAD65 phage vaccine; 2 doses given subcutaneously |
|
Function |
Inducing antigen-specific tolerance is a promising treatment for preventing or reversing Type 1 diabetes (T1D). In contrast to a vaccine that induces immune responses against pathogens, a tolerogenic vaccine can suppress immunity against antigens causing diseases by administrating a mixture of self-antigens with an adjuvant that decreases the strength of antigen-specific response. Kynurenine (Kyn) is an endogenous substance that can inhibit the natural killer cell and T cell proliferation and promote the differentiation of naïve T cells into regulatory T cells (Tregs). In this study, we evaluated the efficacy of Kyn as a novel suppressive adjuvant. Kyn was co-immunized with GAD65 phage vaccine to induce Treg cells and tolerogenic responses for the prevention of T1D in NOD mouse model. Mice were subcutaneously immunized two times with 1011 Pfu (100μL,1012 Pfu/ml) GAD65 phage vaccine doses mixed with 200 μg of Kyn. Serum antibodies and cytokines were detected by ELISA and electrochemiluminescence, respectively. Flow cytometry assay was used to analyze DC and Treg. MTS was used for the analysis of spleen lymphocyte proliferation. RNA sequencing was used to investigate mRNA and miRNA expression profiles in spleen lymphocytes. Compared to GAD65 phage vaccine alone, co-immunization of Kyn and GAD65 phage vaccine resulted in the prevention of hyperglycemia in 60% of mice for at least one month. Further, Kyn enhances GAD65-specific Th2-mediated immune responses; regulates the Th1/Th2 imbalance and increases the secretion of Th2 cytokines and the number of CD4+CD25+Foxp3+T cells; suppresses DC maturation and GAD65-specific T lymphocyte proliferation. Moreover, we integrated Kyn related miRNA and mRNA expression profiles obtained from the spleen lymphocyte RNA-sequencing which was stimulated by Kyn in vitro. These data provide an important basis for understanding the mechanisms underlying Kyn as an immunosuppressive adjuvant which regulated the immune response. These findings suggest that Kyn can serve as an effective suppressive adjuvant candidate for Type 1 diabetes vaccines. |
|
Safety |
Safe in mice; no weight loss or adverse effects; endogenous metabolite with low toxicity profile |
| References |
Sun et al., 2021: Sun J, Shi J, Li J, Wu M, Li Y, Jia S, Ma C, Wang X, Li Z, Hu N, Hu Y. The Effect of Immunosuppressive Adjuvant Kynurenine on Type 1 Diabetes Vaccine. Frontiers in immunology. 2021; 12; 681328. [PubMed: 34305913].
|
|
